Literature DB >> 24002792

Market spiral pricing of cancer drugs.

Donald W Light1, Hagop Kantarjian.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24002792     DOI： 10.1002/cncr.28321

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  21 in total

1.  Cancer care burden: aiming at the Achilles heel.

Authors:  S Ahmed; R K Shahid; K Gesy
Journal:  Curr Oncol       Date:  2015-06       Impact factor: 3.677

2.  The Cancer Drugs Fund in Practice and Under the New Framework.

Authors:  Celia Sabry-Grant; Kinga Malottki; Alexander Diamantopoulos
Journal:  Pharmacoeconomics       Date:  2019-07       Impact factor: 4.981

3.  Approvals in 2016: cost-benefit challenges of new anticancer agents.

Authors:  Philip Savage
Journal:  Nat Rev Clin Oncol       Date:  2017-02-20       Impact factor: 66.675

4.  Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States.

Authors:  Qiushi Chen; Nitin Jain; Turgay Ayer; William G Wierda; Christopher R Flowers; Susan M O'Brien; Michael J Keating; Hagop M Kantarjian; Jagpreet Chhatwal
Journal:  J Clin Oncol       Date:  2016-11-21       Impact factor: 44.544

5.  Clinical trial design and recommendations: collectively, we can take them.

Authors:  Julie Babyar
Journal:  Clin Exp Med       Date:  2017-10-13       Impact factor: 3.984

6.  Value-Based Pricing: Do Not Throw Away the Baby with the Bath Water.

Authors:  Mattias Neyt
Journal:  Pharmacoeconomics       Date:  2018-01       Impact factor: 4.981

7.  Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.

Authors:  Reith R Sarkar; Nicholas J Gloude; Deborah Schiff; James D Murphy
Journal:  J Natl Cancer Inst       Date:  2019-07-01       Impact factor: 13.506

Review 8.  Financial toxicity and implications for cancer care in the era of molecular and immune therapies.

Authors:  George Tran; S Yousuf Zafar
Journal:  Ann Transl Med       Date:  2018-05

9.  Cost-effectiveness analysis of consolidation with brentuximab vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation.

Authors:  Lucy Hui; Gottfried von Keudell; Rong Wang; Amer M Zeidan; Steven D Gore; Xiaomei Ma; Amy J Davidoff; Scott F Huntington
Journal:  Cancer       Date:  2017-06-22       Impact factor: 6.860

Review 10.  The impending financial healthcare burden and ethical dilemma of systemic therapy in metastatic cancer.

Authors:  Muhammad Kashif Riaz; Susan Bal; Trisha Wise-Draper
Journal:  J Surg Oncol       Date:  2016-07-04       Impact factor: 3.454
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.